DDInter1324 DDInter1376
Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells. Ofatumumab was first approved by the FDA in 2009. It is used in the treatment of recurrent, progressive, or recurrent chronic lymphocytic leukemia (CLL) or CLL in treatment-naive patients in whom fludarabine-based therapy is considered inappropriate. Ofatumumab is used as monotherapy or in combination with other medications, depending on the patient profile and previous treatment history. Although it has a similar molecular mechanism of action as [rituximab], another CD-
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Ofatumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ocrelizumab
Ofatumumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Ofatumumab {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Ofatumumab {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Topotecan
Ofatumumab may lead to a major life threatening interaction when taken with Teriflunomide
Ofatumumab may lead to a major life threatening interaction when taken with Etanercept